Literature DB >> 10924536

Presentation, survival and prognostic markers in AA amyloidosis.

N Joss1, K McLaughlin, K Simpson, J M Boulton-Jones.   

Abstract

We reviewed 43 patients with AA amyloidosis who presented to our unit between 1985-1999: 70% had an underlying chronic rheumatological diagnosis. Median (95% CI) patient survival from time of diagnosis was 52.9 months (9.4-96.6) and median renal survival was 18 months (3.2-32.8) Twenty-four patients have died; 42% of deaths were due to infection, while renal failure accounted for 12.5%. Presenting factors which adversely influenced outcome were a low serum albumin and a high 24-h urinary albumin excretion (p=0.007 and p=0.003, respectively). Stepwise multivariate regression analysis identified albuminuria and presenting creatinine clearance as significant predictors. (p=0.005 and p=0.035, respectively). Mean C-reactive protein (CRP) throughout follow-up correlated weakly but not significantly with survival off dialysis (p=0.06). Change in creatinine clearance correlated with albuminuria. (r(2)=40%, p=0.001)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924536     DOI: 10.1093/qjmed/93.8.535

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  17 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Chronic renal failure due to amyloid nephropathy caused by chronic infection after total hip replacement.

Authors:  Shinsuke Nishimura; Tomoji Matsumae; Yuji Murakami; Yasuhiro Abe; Yoshie Sasatomi; Ikufumi Nagayoshi; Kazuo Ueda; Hitoshi Nakashima
Journal:  CEN Case Rep       Date:  2014-04-16

3.  Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Authors:  Tadashi Nakamura; Syu-ichi Higashi; Kunihiko Tomoda; Michishi Tsukano; Masahiro Shono
Journal:  Clin Rheumatol       Date:  2010-05-05       Impact factor: 2.980

4.  Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis.

Authors:  Takeshi Kuroda; Naohito Tanabe; Daisuke Kobayashi; Yoko Wada; Shuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

Review 5.  Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis.

Authors:  Ethan Craig; Laura C Cappelli
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

6.  A young patient with recurrent respiratory tract infection and anasarca.

Authors:  Kosar Hussain; Niaz Ahmed Shaikh; Liza Thomas; Mahmoud M Marashi
Journal:  BMJ Case Rep       Date:  2013-11-11

7.  Heroin Use Is Associated with AA-Type Kidney Amyloidosis in the Pacific Northwest.

Authors:  Arjun Sharma; Priyanka Govindan; Mirna Toukatly; Jack Healy; Connor Henry; Steve Senter; Behzad Najafian; Bryan Kestenbaum
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-15       Impact factor: 8.237

8.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

9.  Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre.

Authors:  Z Potysová; M Merta; V Tesar; E Jancová; E Honsová; R Rysavá
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

10.  Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.

Authors:  Masatoyo Ozawa; Atsushi Komatsuda; Hiroshi Ohtani; Mizuho Nara; Ryuta Sato; Masaru Togashi; Naoto Takahashi; Hideki Wakui
Journal:  Clin Exp Nephrol       Date:  2016-04-26       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.